Riskpilot← Back to searchSign inGet full accessAccess Urologi AB
ABActiveOrg 5592157506Karolinska Vägen 8 A300Medical specialists activities · NACE 8622Est. 201910 employees
Revenue 2024
SEK 136K
+527% vs 2023
EBITDA margin
-6575.8%
-16% vs 2023
Equity ratio
51.6%
Financial strength
Net profit 2024
SEK 3,5M
+37% vs 2023
| Revenue | SEK 136K | +527% |
| EBITDA | SEK -9M | -16% |
| Net profit | SEK 3,5M | +37% |
| Total assets | SEK 7,1M | +15% |
| Equity | SEK 3,7M | +34% |
| Employees | 10 | — |
Legal name
Access Urologi AB
Org number
5592157506
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
22 augusti 2019
Share capital
SEK 50 000
Employees
10 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Specialistvård inom urologi samt därmed förenlig verksamhet.
Address
Karolinska Vägen 8 A300
Email
firaslafta@hotmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | — | 22 | 136 |
| Staff expenses | — | — | −5 220 | −7 642 | −8 976 |
| EBITDA | −1 331 | −3 047 | −5 393 | −7 762 | −8 971 |
| Depreciation & amort. | −25 | −19 | −19 | −18 | −12 |
| EBIT | −1 356 | −3 066 | −5 412 | −7 781 | −8 983 |
| Net financials | 1 399 | 4 956 | 8 262 | 11 313 | 13 642 |
| Profit before tax | 42 | 1 490 | 2 450 | 3 252 | 4 459 |
| Tax | −9 | −307 | −517 | −675 | −931 |
| Net profit | 33 | 1 183 | 1 933 | 2 576 | 3 529 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 996 | 3 022 | 5 134 | 6 178 | 7 077 |
| Equity | 83 | 1 266 | 2 067 | 2 723 | 3 651 |
| Long-term debt | 5 | 5 | 5 | 5 | 5 |
| Short-term debt | 907 | 1 351 | 2 262 | 2 370 | 2 140 |
| Total debt | 912 | 1 356 | 2 267 | 2 375 | 2 145 |
EBITDA margin
-6575.8%
This company
15.8%
Market median
-41719% vs market
20202024
Equity ratio
51.6%
This company
38.2%
Market median
+35% vs market
20202024
Return on equity
96.6%
This company
18.4%
Market median
+425% vs market
20202024
Net profit margin
2586.5%
This company
8.1%
Market median
+31832% vs market
20202024
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20202024
Debt / equity
0.94×
This company
0.62×
Market median
+52% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-08-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SM | Audit | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Access Urologi AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Stig Mikael Siverwall | Audit | 0 companies |
| Luma Al-Sabri | Deputy Board Member | 0 companies |
| Marwan Shareef | Board of Directors | 0 companies |
| Firas Lafta Tarish | Chairman | 0 companies |
| Rowa Basim Jabbar | Deputy Board Member | 0 companies |